PT - JOURNAL ARTICLE AU - Chang, Long-Sheng AU - Oblinger, Janet L. AU - Burns, Sarah S. AU - Huang, Jie AU - Anderson, Lawrence W. AU - Hollingshead, Melinda G. AU - Shen, Rulong AU - Pan, Li AU - Agarwal, Garima AU - Ren, Yulin AU - Roberts, Ryan D. AU - O'Keefe, Barry R AU - Kinghorn, A. Douglas AU - Collins, Jerry M. TI - Targeting protein translation by rocaglamide and didesmethylrocaglamide to treat MPNST and other sarcomas AID - 10.1158/1535-7163.MCT-19-0809 DP - 2019 Jan 01 TA - Molecular Cancer Therapeutics PG - molcanther.0809.2019 4099 - http://mct.aacrjournals.org/content/early/2019/12/17/1535-7163.MCT-19-0809.short 4100 - http://mct.aacrjournals.org/content/early/2019/12/17/1535-7163.MCT-19-0809.full AB - Malignant peripheral nerve sheath tumors (MPNSTs) frequently overexpress eIF4F components, and the eIF4A inhibitor silvestrol potently suppresses MPNST growth. However, silvestrol has suboptimal drug-like properties, including a bulky structure, poor oral bioavailability (<2%), sensitivity to MDR1 efflux, and pulmonary toxicity in dogs. We compared 10 silvestrol-related rocaglates lacking the dioxanyl ring and found that didesmethylrocaglamide (DDR) and rocaglamide (Roc) had growth-inhibitory activity comparable to silvestrol. Structure-activity relationship analysis revealed that the dioxanyl ring present in silvestrol was dispensable for, but may enhance, cytotoxicity. Both DDR and Roc arrested MPNST cells at G2/M, increased the sub-G1 population, induced cleavage of caspases and poly(ADP-ribose) polymerase, and elevated the levels of the DNA-damage response marker γH2A.X, while decreasing the expression of AKT and ERK1/2, consistent with translation inhibition. Unlike silvestrol, DDR and Roc were not sensitive to MDR1 inhibition. Pharmacokinetic analysis confirmed that Roc had 50% oral bioavailability. Importantly, Roc, when administered intraperitoneally or orally, showed potent anti-tumor effects in an orthotopic MPNST mouse model and did not induce pulmonary toxicity in dogs as found with silvestrol. Treated tumors displayed degenerative changes and had more cleaved caspase-3-positive cells, indicative of increased apoptosis. Furthermore, Roc effectively suppressed the growth of osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma cells and patient-derived xenografts. Both Roc- and DDR-treated sarcoma cells showed decreased levels of multiple oncogenic kinases, including IGF-1R. The more favorable drug-like properties of DDR and Roc and the potent anti-tumor activity of Roc suggest that these rocaglamides could become viable treatments for MPNST and other sarcomas.